The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

Classic psychedelics are a chemically diverse group of compounds that act as partial agonists at 5-HT2A serotonin receptors and elicit distinctive subjective effects. The authors note that substances such as psilocybin, DMT (as in ayahuasca), mescaline and LSD have low toxicity and limited abuse liability, and that several recent clinical studies have reported favourable outcomes when these drugs are given under supportive conditions. A central unresolved question is the mechanism of therapeutic action: whether underlying neurobiological changes (for example, enhanced neural plasticity or brain network reorganisation) are sufficient, or whether the first-person subjective experiences engendered by moderate-to-high doses are necessary to produce enduring benefit in humans. Yaden and colleagues set out to argue that certain acute subjective effects are necessary for the full and lasting therapeutic and otherwise beneficial outcomes of psychedelics in humans. They frame this position against an alternative view that regards subjective effects as epiphenomena, summarise psychometric and clinical evidence bearing on the question, and propose a critical experimental test (a thought experiment involving administration under deep anaesthesia) to adjudicate whether subjective experience is essential for durable therapeutic benefit.

Yaden and colleagues review experimental, clinical and survey data linking specific subjective features of psychedelic experiences to longer-term positive outcomes. They highlight the development and use of psychometric instruments, notably the Mystical Experience Questionnaire (MEQ), which operationalises mystical-type experiences across subscales such as unity/connectedness, positively valenced affect, alterations in time and space, and ineffability. Laboratory and clinical studies repeatedly show associations between higher scores on mystical-type or related subjective measures and later benefit. In a double-blind study at Johns Hopkins, 61% of 36 psychedelic-naïve participants met prespecified criteria for a “complete” mystical experience after psilocybin compared with 11% after methylphenidate; follow-up ratings at two months showed greater positive changes attributed to the psilocybin session, and an immediate post-session MEQ score correlated with long-term ratings of personal meaning (r = 0.61) after controlling for three measures of overall drug intensity. A dose–response replication in 18 healthy participants similarly found that mystical experience scores and positive follow-up ratings increased with psilocybin dose. In a randomised double-blind study examining psilocybin combined with meditation, 50 participants received moderate–high doses on two occasions and 25 received low placebo-like doses; 61% of the moderate–high group had complete mystical experiences versus 4% of the low-dose group. Hierarchical regression indicated that MEQ scores on session days substantially improved prediction of a composite measure of positive outcomes (attitudes, mood and behaviour) at six months, increasing the model r-square by 0.54. Clinical trials in patients with life-threatening cancer also linked mystical-type experiences to reductions in anxiety and depression. In one crossover study, mean MEQ percentage of maximum possible score was 64% after a moderate psilocybin dose versus 27% after a low dose; session-day MEQ scores correlated with enduring therapeutic changes at five weeks, and mediation analyses suggested mystical experience partly mediated treatment response. The second crossover study produced similar results. Open-label and dependence treatment studies provide convergent findings. In a smoking cessation trial, 9 of 15 participants (60%) reported a complete mystical experience during at least one psilocybin session; mean session-day MEQ scores correlated with reductions in craving (r = -0.65) and urine cotinine (r = -0.56) at six months, and stronger mystical experiences were associated with biologically verified abstinence. In treatment-resistant depression and major depressive disorder samples, measures related to oceanic boundlessness or peak mystical ratings correlated with reductions in depressive symptoms (for example, r = -0.41 in one MDD study), whereas challenging experience ratings did not show such correlations. Beyond mystical-type experiences, the authors summarise evidence that psychological insight and ‘‘emotional breakthrough’’ are also predictive of positive outcomes. A double-blind comparison of psilocybin and dextromethorphan found psychological or personal insight increased with psilocybin dose and was associated with motivation to use psilocybin. Cross-sectional path analyses and prospective naturalistic surveys suggest that insightful experiences and mystical-type experiences can independently mediate improvements in depression, anxiety and substance use. One open-label psilocybin depression study (N = 24) found a correlation of r = 0.60 between ratings of psychological insight the day after dosing and decreases in depression four weeks later. Across many of these reports, associations between specific subjective features and later benefit remain when statistical controls for overall intensity of the drug effect are applied, and some studies present mediation analyses indicating subjective experiences mediate therapeutic response. The authors acknowledge that non-subjective neurobiological mechanisms observed in animal models (for example, plasticity-related changes) could account for some effects, but they argue these findings do not rule out an essential mediating role for subjective experience in humans.

The authors interpret the reviewed evidence as making a compelling case that certain acute subjective effects occasioned by moderate-to-high doses of classic psychedelics play a key role in enduring therapeutic and other beneficial outcomes. They contend that neurobiological mechanisms are almost certainly necessary but are likely not sufficient to produce the full magnitude and durability of benefit seen in human studies. Much of their argument rests on the repeated finding that measures of mystical-type experience, psychological insight or emotional breakthrough predict longer-term positive change even after controlling for overall intensity of drug effects, and on mediation analyses in several trials. To provide a decisive test of the relevance of subjective effects, Yaden and colleagues propose a critical experiment: administration of a psychedelic while rendering participants fully unconscious (for example, via deep anaesthesia) so they retain no memory of a psychedelic-like subjective experience. They argue that if full and lasting therapeutic efficacy persisted under those conditions, it would refute the necessity of subjective effects; conversely, if efficacy were reduced in magnitude or more transient, that would support their position. The authors describe this as unlikely but logically definitive. They position their view relative to earlier research by acknowledging animal and neurobiological studies that demonstrate plausible mechanisms independent of subjective report, while emphasising that such mechanisms do not negate a mediating role for first-person experience in humans. Limitations acknowledged in the paper include that much of the evidence is preliminary and correlational, and that causality is imperfectly established outside of mediation analyses. The authors do not report conducting new empirical work themselves in this paper; rather, they synthesise existing experimental, clinical and survey findings to support their proposal. In terms of implications, the authors suggest that preserving or facilitating the salient subjective experiences may be important to achieving enduring therapeutic benefit in clinical applications, and they imply that future research should aim to test the proposed anaesthesia-style experiment or otherwise disentangle subjective and neurobiological contributions. They also note that an alternative perspective is available in a companion Viewpoint in the same issue.

Based on experimental studies of moderate-to-high dose psychedelics, Yaden and colleagues conclude that subjective effects likely play a major role in enduring beneficial outcomes. When intensity of the overall psychedelic effect is statistically controlled, certain subjective phenomena predict desirable long-term changes. Neurobiological mechanisms remain important but are probably insufficient on their own to explain the full magnitude and durability of benefit. The authors predict that a nonsubjective ‘‘anaesthesia test’’ would, at most, produce some therapeutic effects but of lower magnitude and/or shorter duration, and they estimate that subjective effects mediate a substantial proportion—possibly the majority—of long-term benefits.